# Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."

> **NCT07686107** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Therapeutic Advances in Childhood Leukemia Consortium** · enrollment: 24 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Revumenib
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine (Ara-C)
- **DRUG:** Methotrexate (IT)
- **DRUG:** Hydrocortisone (intrathecal)
- **DRUG:** Cytarabine (intrathecal)

## Key facts

- **NCT ID:** NCT07686107
- **Lead sponsor:** Therapeutic Advances in Childhood Leukemia Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686107, "Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07686107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*